Published in J Clin Microbiol on December 01, 1996
DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol (2000) 4.71
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol (1997) 3.33
Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol (1999) 2.87
Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol (1997) 2.72
The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol (2008) 2.71
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol (1999) 2.36
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis (2002) 2.26
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J Clin Microbiol (2005) 2.17
Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex. J Clin Microbiol (2002) 2.16
Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol (2001) 2.06
Siderophore production by cystic fibrosis isolates of Burkholderia cepacia. Infect Immun (1998) 1.80
Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III. J Clin Microbiol (2002) 1.79
Invasion and intracellular survival of Burkholderia cepacia. Infect Immun (2000) 1.74
Advances in electronic-nose technologies developed for biomedical applications. Sensors (Basel) (2011) 1.66
The Burkholderia cepacia epidemic strain marker is part of a novel genomic island encoding both virulence and metabolism-associated genes in Burkholderia cenocepacia. Infect Immun (2004) 1.60
Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol (2002) 1.59
Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol (2001) 1.50
Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun (1998) 1.47
Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol (2001) 1.43
Diversity of cultivated endophytic bacteria from sugarcane: genetic and biochemical characterization of Burkholderia cepacia complex isolates. Appl Environ Microbiol (2007) 1.38
Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J Bacteriol (2002) 1.32
Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers. J Clin Microbiol (1997) 1.29
Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol (2000) 1.24
Multilocus sequence typing breathes life into a microbial metagenome. PLoS One (2006) 1.23
A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun (2010) 1.22
Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol (1999) 1.21
Cable-piliated Burkholderia cepacia binds to cytokeratin 13 of epithelial cells. Infect Immun (2000) 1.20
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection. Infect Immun (2002) 1.13
Differential mucoid exopolysaccharide production by members of the Burkholderia cepacia complex. J Clin Microbiol (2008) 1.08
Colonial morphology of Burkholderia cepacia complex genomovar III: implications in exopolysaccharide production, pilus expression, and persistence in the mouse. Infect Immun (2003) 1.08
Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing. J Clin Microbiol (2007) 1.04
Transcriptional response of Burkholderia cenocepacia J2315 sessile cells to treatments with high doses of hydrogen peroxide and sodium hypochlorite. BMC Genomics (2010) 1.01
Genomovar diversity amongst Burkholderia cepacia complex isolates from an Australian adult cystic fibrosis unit. Eur J Clin Microbiol Infect Dis (2003) 1.00
Molecular typing of, and distribution of genetic markers among, Burkholderia cepacia complex isolates from Brazil. J Clin Microbiol (2003) 0.96
Swimming motility in a longitudinal collection of clinical isolates of Burkholderia cepacia complex bacteria from people with cystic fibrosis. PLoS One (2014) 0.92
Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada. J Clin Microbiol (2002) 0.90
Oxidative stress of Burkholderia cenocepacia induces insertion sequence-mediated genomic rearrangements that interfere with macrorestriction-based genotyping. J Clin Microbiol (2009) 0.87
Variation of Burkholderia cenocepacia virulence potential during cystic fibrosis chronic lung infection. Virulence (2016) 0.85
Key role for efflux in the preservative susceptibility and adaptive resistance of Burkholderia cepacia complex bacteria. Antimicrob Agents Chemother (2013) 0.85
Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption. BMC Microbiol (2009) 0.84
Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can J Infect Dis (1998) 0.83
Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis. J Clin Microbiol (2013) 0.82
Random Amplification of Polymorphic DNA Based Typing of Pseudomonas Aeruginosa. Med J Armed Forces India (2011) 0.80
Culture-independent analysis of bacterial fuel contamination provides insight into the level of concordance with the standard industry practice of aerobic cultivation. Appl Environ Microbiol (2011) 0.80
Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex. Antimicrob Agents Chemother (2010) 0.77
Serum susceptibility in clinical isolates of Burkholderia cepacia complex bacteria: development of a growth-based assay for high throughput determination. Front Cell Infect Microbiol (2012) 0.75
Energy-generating enzymes of Burkholderia cepacia and their interactions with macrophages. J Bacteriol (2003) 0.75
Clonality of Bacterial Pathogens Causing Hospital-Acquired Pneumonia. Curr Microbiol (2016) 0.75
A broad-spectrum probe for molecular epidemiology of bacteria: ribosomal RNA. J Infect Dis (1988) 10.73
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting. Nucleic Acids Res (1992) 8.86
Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet (1993) 7.12
Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet (1990) 4.39
Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr (1985) 4.26
Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med (1994) 3.89
Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.74
The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med (1995) 3.36
Molecular epidemiology of Pseudomonas cepacia determined by polymerase chain reaction ribotyping. J Clin Microbiol (1992) 3.13
Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol (1994) 2.74
Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr (1988) 2.60
Research in cystic fibrosis (third of three parts). N Engl J Med (1976) 2.29
Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis (1989) 2.25
Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis (1995) 2.15
Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol (1993) 2.12
Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol (1995) 1.79
Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients. J Clin Microbiol (1995) 1.79
Arbitrarily primed polymerase chain reaction as a rapid method to differentiate crossed from independent Pseudomonas cepacia infections in cystic fibrosis patients. J Clin Microbiol (1993) 1.60
Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia. J Infect Dis (1991) 1.55
Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis. J Clin Microbiol (1993) 1.45
Antibiotic resistance of Pseudomonas species. J Pediatr (1986) 1.36
Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr (1994) 1.36
Comparison of different PCR approaches for characterization of Burkholderia (Pseudomonas) cepacia isolates. J Clin Microbiol (1995) 1.28
Burkholderia cepacia in cystic fibrosis. N Engl J Med (1995) 0.90
Burkholderia cepacia in cystic fibrosis. N Engl J Med (1995) 0.89
Burkholderia cepacia in cystic fibrosis. N Engl J Med (1995) 0.86
Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol (1984) 8.87
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA (2000) 8.06
Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun (1983) 6.24
A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell (1988) 4.68
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun (1994) 3.83
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.74
"Black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology (1996) 3.34
Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol (1997) 3.33
Functional analysis of a herpes simplex virus type 1 promoter: identification of far-upstream regulatory sequences. Nucleic Acids Res (1983) 2.78
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust (1996) 2.78
Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol (1997) 2.72
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
The 65,000-Mr DNA-binding and virion trans-inducing proteins of herpes simplex virus type 1. J Virol (1987) 2.63
Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet (1994) 2.62
Non-prescription use of bronchodilator aerosols. Med J Aust (1992) 2.41
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Attitudes of physicians and public to pharmaceutical industry 'gifts'. Intern Med J (2010) 2.20
Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J (2006) 2.19
Intravenous contrast media: use and associated mortality. Med J Aust (1991) 2.18
Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis (1995) 2.15
Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust (2001) 2.14
Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients. Infect Immun (1984) 2.12
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol (2001) 2.06
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med (2000) 2.04
Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.04
Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis (2001) 2.04
Nonopsonic phagocytosis of nonmucoid Pseudomonas aeruginosa by human neutrophils and monocyte-derived macrophages is correlated with bacterial piliation and hydrophobicity. Infect Immun (1986) 1.80
Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol (1986) 1.76
Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect (1987) 1.74
Serial isolates of Pseudomonas aeruginosa from a cystic fibrosis patient have identical pilin sequences. Infect Immun (1988) 1.68
Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust (1989) 1.68
Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol (2008) 1.63
Cimetidine and ranitidine in duodenal ulcer. Br Med J (1980) 1.63
Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages. Pediatr Res (1987) 1.62
Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis. J Infect Dis (1984) 1.62
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. J Clin Microbiol (1990) 1.60
Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med (1987) 1.59
Fimbriae (pili): molecular basis of Pseudomonas aeruginosa adherence. Clin Invest Med (1986) 1.48
The immediate-early mRNA that encodes the regulatory polypeptide Vmw 175 of herpes simplex virus type 1 is unspliced. EMBO J (1982) 1.47
The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust (1991) 1.47
Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa. Infect Immun (1991) 1.46
Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos (1987) 1.45
Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Infect Immun (1995) 1.45
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (2002) 1.43
Patients as a direct source of information on adverse drug reactions. BMJ (1988) 1.42
Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg (2006) 1.41
Recent changes in the profile of prescription NSAID use in Australia. Med J Aust (2000) 1.41
Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. J Leukoc Biol (1985) 1.40
A tandemly reiterated DNA sequence in the long repeat region of herpes simplex virus type 1 found in close proximity to immediate-early mRNA 1. J Virol (1984) 1.39
Somatostatin in treatment of haematemesis and melaena. Lancet (1985) 1.39
Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed) (1986) 1.38
DNA sequences which regulate the expression of the pseudorabies virus major immediate early gene. Virology (1987) 1.37
A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther (1987) 1.37
Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr (1982) 1.36
Cholestatic hepatitis associated with flucloxacillin. Med J Aust (1993) 1.34
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2000) 1.33
Oxygen-dependent up-regulation of mucoid exopolysaccharide (alginate) production in Pseudomonas aeruginosa. Infect Immun (1990) 1.32
Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun (2000) 1.31
Nonopsonic and opsonic association of Mycobacterium tuberculosis with resident alveolar macrophages is inefficient. J Immunol (1998) 1.29
Serious Pasteurella multocida infections from lion and tiger bites. JAMA (1985) 1.29
The [14C]-aminopyrine breath test. A comparison of different forms of analysis. Br J Clin Pharmacol (1979) 1.26
Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa. Surv Synth Pathol Res (1985) 1.25
Hyponatraemia during carbamazepine treatment. Br Med J (1977) 1.25
In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams. J Antimicrob Chemother (1985) 1.25
Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes O3, O5, and O6. Infect Immun (1994) 1.24
Severe hypokalemia in hospitalized patients. Arch Intern Med (1979) 1.24
Mycobacteria-macrophage interactions. Macrophage phenotype determines the nonopsonic binding of Mycobacterium tuberculosis to murine macrophages. J Immunol (1993) 1.23
Penetration of clinical isolates of Pseudomonas aeruginosa through MDCK epithelial cell monolayers. J Infect Dis (2000) 1.22
Continuous infusion of frusemide in refractory oedema. Br Med J (1978) 1.20
New selective medium for Pseudomonas aeruginosa with phenanthroline and 9-chloro-9-[4-(diethylamino)phenyl]-9,10-dihydro-10- phenylacridine hydrochloride (C-390). J Clin Microbiol (1988) 1.20
Prospective study of computed tomography in acute bacterial meningitis. J Pediatr (1987) 1.20
Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med (1988) 1.18
Alginase treatment of mucoid Pseudomonas aeruginosa enhances phagocytosis by human monocyte-derived macrophages. Infect Immun (1988) 1.16
Congenital lobar emphysema in congenital cytomegalovirus infection. Pediatr Radiol (1996) 1.11
Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. Neuroscience (2005) 1.10
Comparison of agar disk diffusion, microdilution broth, and agar dilution for testing antimicrobial susceptibility of coagulase-negative staphylococci. J Clin Microbiol (1987) 1.09
Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum. Pediatr Res (1984) 1.09
Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. J Gen Intern Med (1999) 1.09
Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg (2002) 1.09
Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages. Infect Immun (1987) 1.08
Ranitidine and cimetidine for duodenal ulcer. Scand J Gastroenterol Suppl (1981) 1.06
Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ Microbiol (2012) 1.06
Evaluation of random amplified polymorphic DNA typing of Pseudomonas aeruginosa. J Clin Microbiol (2000) 1.05
Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother (1991) 1.05
Nonopsonic phagocytosis of Pseudomonas aeruginosa requires facilitated transport of D-glucose by macrophages. J Immunol (1995) 1.04
Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2003) 1.04
Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev (2003) 1.03